Archive for January, 2010

Bayer Starts Clinical Phase I Study With Personalized Vaccine From Tobacco Plants

Sunday, January 31st, 2010

The transfer into clinical development of a patient-specific vaccine represents a milestone for Bayer Innovation GmbH. Following approval of the Phase I study by the FDA (Food & Drug Administration) in the United States, the vaccine is now being tested in human subjects. This is the first time that proteins obtained from tobacco plants using magnICON® technology undergo clinical testing…
Lees meer..

Novo Nordisk Receives US Approval For Victoza® (liraglutide) For The Treatment Of Type 2 Diabetes

Sunday, January 31st, 2010

Novo Nordisk receives US approval for Victoza® (liraglutide) for the treatment of type 2 diabetes Novo Nordisk announced today that the US Food and Drug Administration (FDA) has granted marketing authorisation for Victoza® for the treatment of type 2 diabetes in adults…
Lees meer..

Merck Receives European Approval For ELONVA® (corifollitropin Alfa Injection), A New Fertility Treatment

Sunday, January 31st, 2010

Merck & Co., Inc., which operates outside the U.S. and Canada as MSD, announced the European Commission (EC) approval of ELONVA® (corifollitropin alfa injection). ELONVA is indicated for controlled ovarian stimulation (COS) in combination with a GnRH antagonist for the development of multiple follicles in women participating in an assisted reproductive technology (ART) program…
Lees meer..

GSK’s TYKERB® Receives Accelerated Approval For First-line Combination Treatment Of Hormone Receptor Positive, HER2+/ErbB2+ Breast Cancer

Sunday, January 31st, 2010

GlaxoSmithKline announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for a new combination regimen using TYKERB® (lapatinib) as a first-line, all-oral treatment for women with metastatic breast cancer…
Lees meer..

Rotarix™ Significantly Reduced Severe Rotavirus Gastroenteritis In African Babies During Their First Year Of Life

Sunday, January 31st, 2010

The New England Journal of Medicine (NEJM) published the first study demonstrating that Rotarix™, GlaxoSmithKline’s rotavirus vaccine, significantly prevented severe rotavirus gastroenteritis during the first year of life in African babies. In the study Rotarix prevented the disease in 61.2% of these infants. The study also showed that Rotarix…
Lees meer..

Early Intervention Could Prevent Schizophrenia

Saturday, January 30th, 2010

The onset of schizophrenia is not easy to predict. Although it is associated with as many as 14 genes in the human genome, the prior presence of schizophrenia in the family is not enough to determine whether one will succumb to the mind-altering condition. The disease also has a significant environmental link. According to Prof…
Lees meer..

Renowned Duke Researcher Wins Frontiers Of Knowledge Award

Saturday, January 30th, 2010

The prestigious BBVA Foundation Frontiers of Knowledge Award in the Biomedicine category goes this year to Robert J. Lefkowitz, M.D., James B. Duke Professor of Medicine and Biochemistry and a Howard Hughes Medical Institute (HHMI) investigator at Duke University Medical Center. This is only the second year the award has been given. Dr…
Lees meer..

UCLA Cancer Researchers Perform Complete Genomic Sequencing Of Brain Cancer Cell Line

Saturday, January 30th, 2010

Researchers at UCLA’s Jonsson Comprehensive Cancer Center have performed the first complete genomic sequencing of a brain cancer cell line, a discovery that may lead to personalized treatments based on the unique biological signature of an individual’s cancer and a finding that may unveil new molecular targets for which more effective and less toxic drugs can be developed…
Lees meer..

Walkerton Tragedy: 10 Years Of Research Leads To Breakthrough

Saturday, January 30th, 2010

Studies of the victims of the Walkerton, Ont. tainted drinking water tragedy have led researchers to discover DNA variations in genes that increase the risk of developing post-infectious irritable bowel syndrome (PI-IBS). The sheer scale of infection and the recording of the health of Walkerton’s citizens gave a team of researchers a unique opportunity to study the origin of this disorder…
Lees meer..

Duke To Lead Effort To Better Understand The Role Of Rare Genetic Variation In Clozapine-induced Agranulocytosis Using Whole Genome Sequencing

Saturday, January 30th, 2010

The International Serious Adverse Events Consortium (SAEC) has announced that it will collaborate with Duke University’s Center for Human Genome Variation to research the genetics of Clozapine-induced agranulocytosis (CIA), with the goal of identifying potential rare genetic variants predictive of this serious drug induced adverse event…
Lees meer..